Will you consider additional capecitabine in a patient with TNBC, residual disease after neo-adjuvant chemo, before getting adjuvant pembrolizumab or placebo on SWOG 1418 clinical trial?
Answer from: Medical Oncologist at Academic Institution
We offered adjuvant capecitabine to our TNBC patients with residual disease after neoadjuvant chemo prior to enrolling them on our adjuvant immunotherapy clinical trials.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I would first offer EA 1131 (ECOG-ACRIN) comparing adjuvant capecitabine vs platinum chemotherapy. If she is not eligible, then I would consider adjuvant capecitabine off trial. After adjuvant chemotherapy, or if declined, I would then offer the SWOG 1418 study. I do not believe capecita...
Comments
Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center
Question was supposed to ask, would you consider C...
Question was supposed to ask, would you consider C...
Answer from: Medical Oncologist at Academic Institution
I would definitely offer capecitabine before enrolling them on SWOG 1418. We already have data that capecitabine improves outcomes in TNBC with residual disease after neoadjuvant chemotherapy. I would not feel comfortable depriving a patient from a therapy that has proven beneficial in the phase III...